A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of IPI-145 in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of IPI-145 in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma

Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Duvelisib (Primary) ; Rituximab
  • Indications Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms DYNAMO+R
  • Sponsors Infinity Pharmaceuticals; Verastem
  • Most Recent Events

    • 13 Apr 2017 This trial has been completed in Denmark (End date:2017-03-03) and discontinued in Belgium, according to European Clinical Trials Database.
    • 10 Apr 2017 Status changed from active, no longer recruiting to discontinued.
    • 04 Apr 2017 This trial has been discontinued in Austria (End date:2017-03-03) as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top